07:34 AM EDT, 09/15/2025 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has entered into an agreement to collaborate with Novartis ( NVS ) to develop novel degraders for immune-mediated diseases.

The company said it will receive an upfront payment of $120.0 million. Novartis ( NVS ) also receives options to license two programs from Monte Rosa's preclinical immunology portfolio.

Monte Rosa said it is eligible to receive up to $5.70 billion, including upfront, option maintenance, preclinical milestone, option exercise, and development, regulatory and sales milestone payments across programs. It also will receive tiered royalties on global net sales in the high single to low double-digit range.

This agreement is its second with Novartis ( NVS ). Monte Rosa announced a global exclusive license agreement for its VAV1 degraders including MRT-6160, in October 2024.

Monte Rosa Therapeutics ( GLUE ) shares were up 57% in recent premarket activity.